Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Hormone Refractory”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT00140348
What this trial is testing

Dose Escalation and Efficacy Trial of GVAX® Prostate Cancer Vaccine

Who this might be right for
Prostate Cancer
Cell Genesys 80
Testing effectiveness (Phase 2)Ended earlyNCT00996502
What this trial is testing

Study of Bevacizumab and Erlotinib for Patients With Hormone Refractory Prostate Cancer

Who this might be right for
Prostate Cancer
Columbia University 4
Testing effectiveness (Phase 2)Study completedNCT00987753
What this trial is testing

Study Evaluating the Safety and Tolerability of L-377202

Who this might be right for
Hormone Refractory Prostate CancerProstate Cancer
University of Alabama at Birmingham 13
Early research (Phase 1)Study completedNCT00381173
What this trial is testing

ZYC300 Administered With Cyclophosphamide Pre-Dosing

Who this might be right for
Breast CancerOvarian CancerProstate Cancer+2 more
Eisai Inc. 22
Testing effectiveness (Phase 2)Study completedNCT01518283
What this trial is testing

Study of Weekly Cabazitaxel for Advanced Prostate Cancer

Who this might be right for
Hormone Refractory Prostate Cancer
Spanish Oncology Genito-Urinary Group 74
Large-scale testing (Phase 3)Study completedNCT00116142
What this trial is testing

Hormone Suppression and Radiation Therapy for 6 Months With/Without Docetaxel for High Risk Prostate Cancer

Who this might be right for
Prostate Cancer
Dana-Farber Cancer Institute 350
Testing effectiveness (Phase 2)Study completedNCT00459654
What this trial is testing

A Placebo-controlled Phase II Study of Bone-targeted Radium-223 in Symptomatic Hormone-refractory Prostate Cancer

Who this might be right for
Prostate CancerNeoplasm Metastasis
Bayer 64
Testing effectiveness (Phase 2)Ended earlyNCT01194960
What this trial is testing

TroVax® In Subjects With Hormone Refractory Prostate Cancer (HRPC)

Who this might be right for
Hormone Refractory Prostate Cancer
Oxford BioMedica 25
Testing effectiveness (Phase 2)Study completedNCT01487720
What this trial is testing

GEMOX in Docetaxel-Refractory Castration-Resistant Prostate Cancer

Who this might be right for
Prostate Cancer
Asan Medical Center 33
Large-scale testing (Phase 3)Study completedNCT00002760
What this trial is testing

Antiandrogen Withdrawal in Treating Patients With Hormone-Refractory Prostate Cancer

Who this might be right for
Prostate Cancer
Alliance for Clinical Trials in Oncology 260
Testing effectiveness (Phase 2)Study completedNCT00766324
What this trial is testing

PHA-739358 for Treatment of Hormone Refractory Prostate Cancer

Who this might be right for
Metastatic Hormone Refractory Prostate Cancer
Nerviano Medical Sciences 118
Testing effectiveness (Phase 2)Study completedNCT00017576
What this trial is testing

Calcitriol and Carboplatin in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy

Who this might be right for
Prostate Cancer
OHSU Knight Cancer Institute 19
Testing effectiveness (Phase 2)Study completedNCT00416533
What this trial is testing

Docetaxel, Doxorubicin, and Prednisone in Treating Patients With Advanced Prostate Cancer That Has Not Responded to Hormone Therapy

Who this might be right for
Prostate Cancer
Wake Forest University Health Sciences 47
Large-scale testing (Phase 3)Study completedNCT00887198
What this trial is testing

Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer

Who this might be right for
Prostate Cancer
Janssen Research & Development, LLC 1,088
Testing effectiveness (Phase 2)Study completedNCT00488982
What this trial is testing

Intermittent Chemotherapy With or Without Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) for Metastatic Hormone Refractory Prostate Cancer (HRPC)

Who this might be right for
Prostate Cancer
University of California, San Francisco 125
Testing effectiveness (Phase 2)Study completedNCT00124566
What this trial is testing

Study of Irofulven in Patients With Hormone-refractory Prostate Cancer

Who this might be right for
Prostate Cancer
Eisai Inc. 135
Testing effectiveness (Phase 2)Looking for participantsNCT05579366
What this trial is testing

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

Who this might be right for
High Grade Epithelial Ovarian CancerHigh Grade Serous Ovarian CancerPrimary Peritoneal Carcinoma+12 more
Genmab 884
Testing effectiveness (Phase 2)Ended earlyNCT00183937
What this trial is testing

Study of Bortezomib and Docetaxel for Patients With Hormone Refractory Prostate Cancer

Who this might be right for
Prostate Cancer
University of Southern California 15
Early research (Phase 1)Study completedNCT00405210
What this trial is testing

Pharmacokinetic Study of BAY43-9006 and Taxotere to Treat Patient With Prostatic Cancer

Who this might be right for
Primary DiseaseProstate Cancer
Cliniques universitaires Saint-Luc- Université Catholique de Louvain 38
Testing effectiveness (Phase 2)Study completedNCT01560923
What this trial is testing

Phase II Study of Sipuleucel-T and Indoximod for Patients With Refractory Metastatic Prostate Cancer

Who this might be right for
Metastatic Prostate Cancer
Masonic Cancer Center, University of Minnesota 47
Next Page